Clinical Research Directory
Browse clinical research sites, groups, and studies.
Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease
Sponsor: New York Medical College
Summary
This study is being done to determine the safety and outcome (long-term control) of a high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem cells from a partially matched adult family member donor, called haploidentical stem cell transplantation, in high-risk sickle cell disease patients. Funding Source - FDA OOPD
Official title: Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)
Key Details
Gender
All
Age Range
2 Years - 20 Years
Study Type
INTERVENTIONAL
Enrollment
21
Start Date
2012-01
Completion Date
2026-12
Last Updated
2025-08-08
Healthy Volunteers
No
Conditions
Interventions
CD34 selected T-cell depleted allogeneic SCT
Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
Locations (6)
University of California Los Angeles (UCLA)
Los Angeles, California, United States
Children's Hospital and Research Center Oakland
Oakland, California, United States
Lurie Children's Hospital
Chicago, Illinois, United States
Washington University/St. Louis Children's Hospital
St Louis, Missouri, United States
New York Medical College
Valhalla, New York, United States
Medical College of Wisconsin/Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States